Capricor Therapeutics, Inc. (CAPR) has a negative trailing P/E of -14.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 178.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -6.85%, forward earnings yield 0.56%. PEG 1.29.
Criteria proven by this page:
Overall SharesGrow Score: 62/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.6 | -0.10 | -12.33 | 15.47 | - |
| 2017 | 15.1 | -0.14 | 3.26 | 13.74 | - |
| 2018 | -0.8 | 0.00 | 2.61 | 7.21 | - |
| 2019 | -0.6 | 0.01 | 0.69 | 4.73 | - |
| 2020 | -3.9 | 0.07 | 1.89 | 172.15 | - |
| 2021 | -3.4 | 2.97 | 2.16 | 276.24 | - |
| 2022 | -3.3 | -0.09 | 8.04 | 37.15 | - |
| 2023 | -5.9 | 0.20 | 5.79 | 5.20 | - |
| 2024 | -12.0 | -0.31 | 3.34 | 21.82 | - |
| 2025 | -12.8 | -0.13 | 4.39 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-10.14 | $3.19M | $-18.81M | -589.6% |
| 2017 | $0.90 | $2.67M | $2.43M | 91.2% |
| 2018 | $-5.17 | $1.67M | $-15.19M | -909.1% |
| 2019 | $-2.06 | $1.01M | $-7.64M | -760.4% |
| 2020 | $-0.88 | $310.25K | $-13.66M | -4401.9% |
| 2021 | $-0.87 | $244.9K | $-20.02M | -8176.1% |
| 2022 | $-1.18 | $2.55M | $-29.02M | -1137.6% |
| 2023 | $-0.83 | $25.18M | $-22.29M | -88.5% |
| 2024 | $-1.15 | $22.27M | $-40.47M | -181.7% |
| 2025 | $-2.26 | $0.00 | $-105.04M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.20 | $-1.49 – $1.47 | $149.82M | $919.94K – $304.89M | 8 |
| 2027 | $-0.24 | $-0.68 – $0.34 | $117.59M | $13.35M – $291.46M | 6 |
| 2028 | $2.04 | $1.04 – $4.94 | $278.89M | $16.23M – $595.1M | 5 |
| 2029 | $4.03 | $-0.90 – $9.98 | $449.11M | $26.14M – $958.32M | 1 |
| 2030 | $6.31 | $-1.42 – $15.62 | $683.66M | $39.79M – $1.46B | 1 |
